Loading
AS
Asensus Surgical, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 18 Dec 2023.
Asensus Surgical, Inc.: what insiders have been doing
Asensus Surgical, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). No insider at Asensus Surgical, Inc. has published a filing in the past twelve months. The most recent one dates from 22 August 2024.
Over the whole record (from 2016), the tally stands at 4 purchases and 1 sale.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
48
Thresholds
n/a
Buy Volume
€238,023
4 ops. · all time
Sell Volume
€10,373
1 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$7.4M
Gross profit-US$3.9M-53% margin
Net income-US$67.5M-914.5% margin
Last declaration on 22 August 2024
Declarations48 total
189,417 sharesCommon StockSEC:0001437749-24-027545:0
492,815 sharesCommon StockSEC:0001437749-24-027541:0
117,201 sharesCommon StockSEC:0001437749-24-027547:0
595,372 sharesCommon StockSEC:0001437749-24-027542:0
13,846 sharesCommon StockSEC:0001437749-24-027540:0
2,611,203 sharesCommon StockSEC:0001437749-24-027543:0
619,884 sharesCommon StockSEC:0001437749-24-027544:0
54,201 sharesCommon StockSEC:0001437749-24-027546:0
81,521 shares0Common StockSEC:0001437749-24-012886:0
271,739 shares0Common StockSEC:0001437749-24-012885:0
119,429 shares@ US$0.255.4% of flowCommon StockSEC:0001437749-24-012885:1
43,638 shares@ US$0.258.4% of flowCommon StockSEC:0001437749-24-012886:1
280,909 shares0Common StockSEC:0001437749-24-003268:0
1,042,772 shares0Common StockSEC:0001437749-24-003267:0
484,572 shares@ US$0.2723.1% of flowCommon StockSEC:0001437749-24-003267:1
150,367 shares@ US$0.2730.7% of flowCommon StockSEC:0001437749-24-003268:1
18,134 shares@ US$0.2831.0% of flowCommon StockSEC:0001209191-23-059023:0
Canonical exit: 13 Mar 2024 (T+90)
16,666 shares0Common StockSEC:0001209191-23-041221:0
45,000 shares0Common StockSEC:0001209191-23-035502:0
45,000 shares0Common StockSEC:0001209191-23-035521:0
293,077 shares@ US$0.7082100.0% of flowCommon StockSEC:0001209191-23-016567:0
Canonical exit: 1 Jun 2023 (T+90)
248,512 shares0Common StockSEC:0001209191-23-007655:0
1,207,002 shares0Common StockSEC:0001209191-23-007653:0
541,726 shares@ US$0.7571.5% of flowCommon StockSEC:0001209191-23-007653:1
103,998 shares@ US$0.7558.8% of flowCommon StockSEC:0001209191-23-007655:1
25 of 48 declarations
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is a medical technology company focused on robotic-assisted surgery and digitally enhanced minimally invasive procedures. The company traces its roots to TransEnterix and rebranded as Asensus Surgical in 2021 to better reflect its strategic shift toward data-driven surgical care and what it describes as Performance-Guided Surgery™. Its headquarters are in Research Triangle Park, North Carolina, United States. Before being acquired in August 2024, Asensus was listed on the NYSE American under the ticker ASXC. For investors, the key point is that the company is no longer independently traded after the completion of that transaction.
At the center of Asensus’ business model was the Senhance Surgical System, a robotic-assisted platform designed to bring digital laparoscopy into routine operating-room use. The company also marketed the Intelligent Surgical Unit (ISU), an enabling system that added advanced visualization, augmented-intelligence features, and software-based support for surgeons. In parallel, Asensus was developing the LUNA Surgical System, intended as a next-generation robotic and instrument platform. Taken together, these offerings positioned the company in the fast-evolving segment of digital surgery, where the competitive edge depends not only on robotics hardware but also on software, analytics, workflow integration, and surgeon support tools.
Read moreShow less
From a competitive standpoint, Asensus was a niche player in a market dominated by larger and much better capitalized medtech groups. That scale disadvantage was partly offset by a differentiated value proposition: lower-cost digital surgery concepts, real-time guidance features, and an emphasis on improving precision and consistency in minimally invasive surgery. The company’s systems were relevant across general surgery and selected specialty applications, with a particular focus on areas such as urology. Its positioning was therefore more innovative and technology-led than volume-led, which made it strategically interesting but financially more exposed than larger peers.
Geographically, Asensus had an international footprint, with placements and commercial activity in North America, Europe, and Asia, including Japan and several European markets. Recent milestones included a 2024 FDA clearance expanding the Senhance system’s U.S. indication into urology, followed by the definitive acquisition by KARL STORZ, completed in August 2024. That deal ended ASXC’s life as a standalone public equity story on the NYSE American. For French, Belgian, and Swiss investors, Asensus is best understood today as a former listed U.S. surgical robotics company whose technology assets and product platform were absorbed into a larger global medtech group.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
